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The presence of human papillomavirus (HPV) was evaluated in 65 samples of prostate tumours and six samples 
of prostates with benign prostatic hyperplasia from individuals from Northern Brazil. We used a highly sensitive test, 
the Linear Array HPV Genotyping Test, to detect 37 high and low-risk HPV types. In this study, only 3% of tumour 
samples showed HPV infection. Our findings support the conclusion that, despite the high incidence of HPV infection 
in the geographic regions studied, HPV was not associated with a higher risk of prostate cancer. To our knowledge, 
this is the first study evaluating the frequency of HPV detection in prostatic tissue of individuals from Brazil.
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Prostate cancer is the fifth most common cancer in 
the world and the second most common cancer in men 
(Parkin et al. 2005). In Brazil, an estimated 49,530 cases 
were newly diagnosed in 2008. However, in Northern 
Brazil, the incidence rates are lower than the national 
average rate (INCA 2007).
In general, inflammation is associated with multiple 
cancers and prostate inflammation, in particular, has 
been suggested to be a factor in the development and 
progression of prostate cancer. Infections, particularly 
sexually transmitted and other ascending urogenital in-
fections, are possible causes of intraprostatic inflamma-
tion and/or prostate cancer. Infectious organisms have 
been described to be important for the maintenance 
of local inflammation processes and can be responsi-
ble for the cellular alterations that lead to genetic and 
epigenetic alterations bringing cells to transformation 
(De Marzo et al. 2007).
Several studies have suggested that the ethnic differ-
ences observed in the incidence rates of prostate cancer 
could be derived from cultural variations in sexual be-
haviour. The possible relationship between high risk hu-
man papillomavirus (HPV) infection and prostate cancer 
has been investigated previously (Anwar et al. 1992, Tu 
et al. 1994, Strickler & Goedert 2001, Adami et al. 2003, 
Carozzi et al. 2004, May et al. 2008).
HPV codes for the oncoproteins E6 and E7 that 
are able to immortalise many cellular types, including 
prostate tissue cells, in vitro through the inactivation of 
the tumour suppressor genes, P53 and PRb (Choo et al. 
1999). Epidemiological data also demonstrate that men 
with a history of anal cancer, a tumour associated with 
HPV infection, have an increased risk of developing 
prostate cancer (Rabkin et al. 1992). A clear association 
between HPV infection and the development of prostate 
cancer and/or progression has still not been established. 
To our knowledge, this is the first study evaluating the 
frequency of HPV infection in individuals with pros-
tate cancer in Brazil. This study aims to detect high and 
low-risk HPV DNA, using a highly sensitive assay, in 
samples of prostate tumours and of prostates with be-
nign prostatic hyperplasia (BPH), from individuals from 
Northern Brazil.
The study included 65 cases of prostate cancer and 
six cases of BPH from patients who underwent sur-
gical treatment. For each patient with BPH, samples 
were obtained from the urothelial region in the ure-
thra and from the deep prostate tissue (without urothe-
lial cells). Specimens were obtained from patients of 
several hospitals of state of Pará, Northern Brazil. 
All patients had negative histories of exposure to ei-
ther chemotherapy or radiotherapy prior to surgery 
and the patients had no other diagnosed cancers. In-
formed consent with approval of the ethics commit-
tee of João de Barros Barreto University Hospital was 
obtained from all patients.
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Tumours were staged using standard criteria by 
Gleason score and TNM staging. No sample had a Glea-
son score lower than 5. Table shows the cases along with 
their clinico-pathological characteristics
To extract DNA, tumour fragments and BPH samples 
were incubated in 200 µL TE solution (1 mM EDTA, Tris 
10 mM, pH 7.4) with 20 mg/mL of proteinase K at 65°C 
overnight or until complete fragment digestion. Subse-
quently, the proteinase K was inactivated at 95°C for 15 
min and the total product was used for phenol-chloro-
form DNA extraction. The Linear Array HPV Genotyp-
ing Test (Roche Molecular Diagnostic, Alameda, CA) 
was used for HPV detection in 100 ng DNA samples. 
The Linear Array test uses the PGMY09/11 L1 consen-
sus primer system to amplify a HPV fragment of 450 bp 
and includes coamplification of a human cellular target, 
β-globin, as a control to DNA viability. Positive and neg-
ative HPV samples provided with the Linear Array HPV 
Genotyping Test were used as controls. Detection and 
HPV genotyping were achieved using a reverse line-blot 
method, and this test included probes to the genotypes 
of 37 high and low-risk HPV types [6, 11, 16, 18, 26, 31, 
33, 35, 39, 40, 42, 45, 51, 52, 54, 55, 56, 58, 59, 61, 62, 
64, 66, 67, 68, 69, 70, 71, 72, 73(MM9), 81, 82(MM4), 
83(MM7), 84(MM8), IS39 and CP6108].
The PCR reaction was carried out using the follow-
ing conditions; 2 min at 50°C followed by 9 min at 95°C; 
then, 40 cycles at 95°C for 30 s, 55°C for 1 min and 72°C 
for 1 min. Finally, reactions were subjected to a final 
extension for 5 min at 72°C. PCR products were sepa-
rated by electrophoresis through a 1% agarose gel and 
the denatured PCR products were hybridised onto the 
strip containing specific probes for 37 HPV genotypes 
and β-globin reference lines.
Adequate samples were those that showed β-globin 
amplification fragments in the agarose gel and in the 
strip after PCR product hybridization. HPV-positive 
samples were those that showed any hybridization line 
corresponding to a high and/or low-risk HPV type. 
The strips were interpreted using the HPV reference 
guide provided. Results from specimens that failed to 
amplify the β-globin internal control, indicating poor 
DNA recovery and an invalid sample, were excluded 
from the study.
No BPH samples from the urothelial region or from 
deep prostate tissue showed HPV infection. Only two 
of 65 (3%) tumour samples showed HPV fragments and 
both of these were HPV 16 (Figure). All HPV 16-in-
fected patients were co-infected with HPV 84. The two 
HPV-positive samples were classified as pT3aN1M0 and 
had a concerning, high grade Gleason score (final score 
of 8 and 9). The two patients with HPV infection were 
62 and 65 years old.
Many different pathogenic organisms can cause an 
inflammatory response in the prostate. Viral infections 
such as HPV, human herpes simplex virus type 2, cyto-
megalovirus and human herpes virus type 8 have been 
detected in prostate tissue. McNicol and Dodd (1990a, b) 
observed a high frequency of HPV infection in BPH and 
prostatic carcinoma samples. Other studies also found a 
possible association between HPV and prostate carcino-
genesis (Anwar et al. 1992, Kuczyk et al. 2000, May et 
al. 2008). However, a clear association between HPV in-
fection and prostate cancer has not been established.
To evaluate the frequency of HPV infection in pros-
tatic samples, we used the Linear Array HPV Genotyp-
ing Test, a sensitive assay for the detection of a large 
spectrum of HPV types. The Linear Array HPV Geno-
typing Test also has β-globin reference lines to guar-
antee the quality of DNA extraction and exclude some 
false negatives.
In the present study, only 3% of prostate carcinoma 
samples showed HPV (16 and 84) infection and no BPH 
samples showed infection. Although HPV 16 has been 
associated with the carcinogenesis process, our findings 
corroborated those from other studies that did not find 
any association between HPV infection and prostate 
cancer due to the low frequency of this virus in pros-
tatic samples (Ibrahim et al. 1992, Wideroff et al. 1996, 
Noda et al. 1998, Strickler et al. 1998, Saad et al. 1999, 
Adami et al. 2003). Thus, these studies do not support an 
aetiological role of HPV in prostate cancer. Moreover, 
HPV 84 is classified as a type with low oncogenic risk 
and tends to occur as a multiple-type infection involving 
HPV 16 (Franco et al. 1999).
The low frequency of HPV that we found in prostate 
samples is probably not related to a low risk of sexu-
ally transmitted diseases in our population. In 2007, we 
observed a high incidence of HPV infection in Amazon 
communities in Northern Brazil. HPV was detected in 
TABLE
Clinico-pathological characteristics of the samples
Variable
Samples
BPH
(n = 6)
Prostatic tumors
(n = 65)
Mean age (SD) 64 ± 13.9 62 ± 7.3
Surgery % %
   Trans-urethral prostate resection 100 0
   Total prostatectomy 0 100
Grade % %
   Low (Gleason 2-6) - 40
   Moderate (Gleason 7) - 26.2
   High (Gleason 8-10) - 33.8
Tumor extension % %
   T1 - 0
   T2 - 56.9
   T3 - 36.9
   T4 - 6.2
Regional lymph nodes % %
   Absent - 66.2
   Present - 33.8
Distant metastasis % %
   Absent - 86.2
   Present - 13.8
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31.64% of 158 histologically-normal penile and vaginal 
smears, using the Linear array HPV Genotyping Test 
(unpublished observations).
To our knowledge, this is the first study evaluating 
the presence of HPV in prostate tissue of individuals 
from Brazilian populations. Our findings do not support 
the involvement of HPV in the aetiology or progression 
of prostate carcinogenesis.
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